0001193125-12-363485.txt : 20120821 0001193125-12-363485.hdr.sgml : 20120821 20120821160152 ACCESSION NUMBER: 0001193125-12-363485 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120821 FILED AS OF DATE: 20120821 DATE AS OF CHANGE: 20120821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: China Kanghui Holdings CENTRAL INDEX KEY: 0001495660 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34840 FILM NUMBER: 121047799 BUSINESS ADDRESS: STREET 1: NO.1-8 TIANSHAN ROAD STREET 2: XINBEI DISTRICT CITY: CHANGZHOU STATE: F4 ZIP: 213022 BUSINESS PHONE: 86519-85195556 MAIL ADDRESS: STREET 1: NO.1-8 TIANSHAN ROAD STREET 2: XINBEI DISTRICT CITY: CHANGZHOU STATE: F4 ZIP: 213022 6-K 1 d400813d6k.htm FORM 6-K Form 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the month of August 2012

Commission File Number 001-33535

 

 

China Kanghui Holdings

(Translation of Registrant’s Name Into English)

 

 

No.1-8 Tianshan Road, Xinbei District

Changzhou, Jiangsu Province 213022, People’s Republic of China

(86-519) 8519-5556

(Address of Principal Executive Offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  x        Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes  ¨            No  x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-            

 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

China Kanghui Holdings
By:  

/S/    JUNWEN WANG        

Name:   Junwen Wang
Title:   Chief Financial Officer

Date: August 21, 2012


China Kanghui Holdings Reports Second Quarter 2012 Financial Results

2Q12 Net Revenue Increased 23.6% Year-Over-Year

2Q12 Net Income Increased 24.7% Year-Over-Year

CHANGZHOU, August 21, 2012 – China Kanghui Holdings (NYSE: KH) (“Kanghui” or the “Company”), a leading domestic developer, manufacturer and marketer of orthopedic implants in China, today announced its unaudited financial results for the second quarter of 2012.

Second Quarter 2012 Highlights

 

   

Total net revenue for the second quarter of 2012 increased by 23.6% year-over-year to RMB101.1 million from RMB81.8 million in the corresponding period of the prior year.

 

   

Gross profit for the second quarter of 2012 increased by 24.0% year-over-year to RMB71.9 million from RMB58.0 million in the corresponding period of the prior year.

 

   

Operating income for the second quarter of 2012 increased by 27.3% year-over-year to RMB38.7 million from RMB30.4 million in the corresponding period of the prior year.

 

   

Net income attributable to Kanghui for the second quarter of 2012 increased by 24.7% year-over-year to RMB34.8 million from RMB27.9 million in the corresponding period of the prior year.

 

   

Non-GAAP1 net income for the second quarter of 2012 increased by 33.0% year-over-year to RMB39.1 million from RMB29.4 million in the corresponding period of the prior year.

 

1 

All non-GAAP measures exclude share-based compensation expenses. For further details on non-GAAP measures, please refer to the reconciliation tables and a detailed discussion of the Company’s use of non-GAAP information set forth elsewhere in this press release.

2 

This announcement contains translations of certain Renminbi (“RMB”) amounts into US dollars (“$”) at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to US dollars as of and for the quarter ended June 30, 2012 were made at the noon buying rate of RMB6.3530 to $1.00 on June 29, 2012 in the City of New York for cable transfers in Renminbi per US dollar as certified for customs purposes by the Federal Reserve Bank of New York. The Company makes no representation that the Renminbi or US dollar amounts referred to in this press release could have been or could be converted into US dollars or Renminbi, at any particular rate or at all.

3 

Each of the Company’s American Depositary Shares (“ADS”), which are traded on New York Stock Exchange, represents six of the Company’s ordinary shares.


Mr. Libo Yang, Chief Executive Officer of the Company, stated, “We are delighted that Kanghui’s second quarter marked another strong performance. Growth from trauma and spine sales remained robust, and we further expanded our product offerings by launching our joint reconstruction product into the international markets, while adding another new spine product exclusively marketed in China. Domestic sales were strong, as we continued to gain momentum throughout China. With unabated strong demand and promising new product launches, we believe we are well positioned for sustained success going forward.”

Ms. Sarah Wang, Chief Financial Officer of Kanghui, commented, “I am proud that Kanghui delivered our eighth consecutive strong quarter since its initial public offering, with our first-ever quarter of recording over RMB 100 million in net revenue. Our outstanding growth in net revenue, along with double-digit growth in key operating metrics, exemplify the strength of our business model. Benefiting from the strong domestic sales of our proprietary products, our gross profit margins continued to exceed expectations, and as we build on this positive momentum, we are incrementally more confident in outlook for the remainder of 2012.”

Second Quarter 2012 Financial and Operating Results

Net revenue increased by 23.6% year-over-year to RMB101.1 million ($15.9 million)2 in the second quarter of 2012 from RMB81.8 million in the corresponding period of the prior year.

Net revenue by product category:

Net revenue from trauma products increased by 25.3% year-over-year to RMB59.5 million ($9.4 million) in the second quarter of 2012 from RMB47.5 million in the corresponding period of the prior year. Net revenue from spine products increased by 24.3% year-over-year to RMB32.7 million ($5.1 million) in the second quarter of 2012 from RMB26.3 million in the corresponding period of the prior year. Net revenue from OEM products increased by 11.3% year-over-year to RMB8.9 million ($1.4 million) in the second quarter of 2012 from RMB8.0 million in the corresponding period of the prior year. Joint Reconstruction products initialed sales in June, and generated net revenue of RMB102,000 ($16,000) in the second quarter of 2012.

Net revenue by geographic markets:

Domestic sales of proprietary products increased by 34.7% year-over-year to RMB77.6 million ($12.2 million) in the second quarter of 2012 from RMB57.6 million in the corresponding period of the prior year, while international sales of proprietary products decreased by 8.7% year-over-year to RMB14.7 million ($2.3 million) in the second quarter of 2012 from RMB16.1 million in the corresponding period of the prior year. The decrease in international sales was primarily attributable to the Company’s strategic shift in production to fulfill the strong domestic orders, as well as lower sales in the Middle East due to the region’s political instability.

 

4 

Beginning in the first quarter 2012, in accordance with Accounting Standards Update 2011-05, the Company is presenting other comprehensive income and its components in the unaudited condensed consolidated Statement of Comprehensive Income. Other comprehensive income mainly consists of currency translation adjustments relating to the translation of our subsidiaries’ financial statements from their functional currency to our reporting currency, which is in the United States dollar. The functional currency of our main subsidiaries in China is the RMB.


In the second quarter of 2012, cost of revenue increased by 23.2% year-over-year to RMB29.2 million ($4.6 million) from RMB23.7 million in the corresponding period of the prior year. Gross profit increased by 24.0% year-over-year to RMB71.9 million ($11.3 million) in the second quarter of 2012 from RMB58.0 million in the corresponding period of the prior year. Gross margin for the second quarter of 2012 was 71.1%, compared to 71.0% in the corresponding period of the prior year.

Selling expenses decreased by 1.7% year-over-year to RMB11.6 million ($1.8 million) in the second quarter of 2012 from RMB11.8 million in the corresponding period of the prior year. General and administrative expenses increased by 28.4% year-over-year to RMB18.1 million ($2.8 million) in the second quarter of 2012 from RMB14.1 million in the corresponding period of the prior year. Research and development expenses increased by 88.9% year-over-year to RMB3.4 million ($0.5 million) in the second quarter of 2012 from RMB1.8 million in the corresponding period of the prior year.

Operating income increased by 27.3% year-over-year to RMB38.7 million ($6.1 million) in the second quarter of 2012 from RMB30.4 million in the corresponding period of the prior year. Operating margin increased to 38.3% in the second quarter of 2012 from 37.2% in the corresponding period of the prior year.

Income tax expense in the second quarter of 2012 was RMB6.5 million ($1.0 million), representing an effective tax rate of 15.8%, compared to an income tax expense of RMB3.8 million, and an effective tax rate of 12.0% in the corresponding period of the prior year.

Net income attributable to China Kanghui Holdings was RMB34.8 million ($5.5 million) in the second quarter of 2012, representing a year-over-year increase of 24.7% from RMB27.9 million in the corresponding period of the prior year. On a diluted per ADS3 basis, the Company reported net income per diluted ADS of RMB1.33 ($0.21) in the second quarter of 2012, compared to a net income per diluted ADS of RMB1.09 in the corresponding period of the prior year.

Non-GAAP net income, which excludes share-based compensation expenses, increased by 33.0% to RMB39.1 million ($6.2 million) from RMB29.4 million in the corresponding period of the prior year. The Company reported non-GAAP net income per diluted ADS of RMB1.50 ($0.24) in the second quarter of 2012, compared to a non-GAAP net income per diluted ADS of RMB1.11 in the corresponding period of the prior year.


During the second quarter of 2012, the Company had a weighted average diluted share count of 156.3 million shares (equivalent to 26.1 million ADSs), compared to 153.7 million shares (equivalent to 25.6 million ADSs) in the corresponding period of the prior year.

Balance Sheet

As of June 30, 2012, the Company had cash and cash equivalents of RMB432.1 million ($68.0 million), compared to RMB380.1 million as of December 31, 2011. As of June 30 2012, the Company held short-term investments of RMB10.3 million ($1.6 million), compared to RMB77.0 million as of December 31, 2011.

Business Outlook

Mr. Yang added, “Our solid performance in the first half of 2012 and the recent successful new product launches have set the stage for continued success in the remainder of 2012, providing us with greater comfort in our top line forecast. Moreover, reflecting on our strong gross margins and continuing discipline in optimizing operations and controlling overhead costs, we are slightly raising our full year 2012 guidance for Non-GAAP net income.”

The Company narrows its total net revenue outlook for full year 2012 to be in the range of RMB395 million to RMB403 million, which represents year-over-year growth of 20.8% to 23.3%. The Company raises its full year 2012 non-GAAP net income to a range of RMB149 million to RMB154 million, from its prior expectation of RMB146 million to RMB153 million.

This guidance is based on the current market conditions and reflects the Company’s current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change.

Non-Cash Share-Based Compensation Expenses

The Company recognized non-cash share-based compensation expenses of RMB4.4 million ($0.7 million) in the second quarter of 2012.

The Company classified these non-cash share-based compensation expenses in its costs of revenue, selling expenses, general and administrative expenses as well as in research and development expenses. The break out of these expenses per line item is provided in the financial tables attached to this press release.

The Company has provided a non-GAAP presentation of results, which excludes the non-cash share-based compensation expenses. Please refer to the non-GAAP presentation provided in the appendix for a year-over-year comparison of non-cash share-based compensation expenses. The Company believes that this non-GAAP presentation is a helpful tool for the Company to plan and forecast future periods and both management and investors benefit from referring to such non-GAAP presentation in assessing the performance of the Company.


Conference Call

Kanghui will hold a corresponding conference call and live webcast at 8:00 a.m. ET (8:00 p.m. Beijing Time) on Wednesday, August 22, 2012 to discuss second quarter 2012 results and answer questions from investors. Listeners may access the call by dialing:

 

US Toll Free:    1-866-519-4004
US Toll/International:    1-718-354-1231
Hong Kong Toll Free:    800-930-346
Hong Kong Toll:    852-2475-0994
China Toll Free:    800-819-0121
China Toll Free (Mobile):    400-620-8038
Conference ID:    12464049

A replay of the webcast will be accessible through August 29, 2012 on http://ir.kanghui.com or by dialing:

 

United States toll free:    1-866-214-5335
US Toll/International:    1-718-354-1232
Passcode:    12464049

About China Kanghui Holdings

Founded in 1997, Kanghui is a leading domestic developer, manufacturer and marketer of orthopedic implants in China. The Company offers a wide array of proprietary orthopedic implant products in trauma, spine and joint reconstruction, and has an extensive nationwide network of distributors for its products in China, as well as in 29 other countries, as of June, 30, 2012. Kanghui has strong research and development capabilities, focused on developing new proprietary products and product lines, and enhancing existing products and product lines. For more information, please visit www.kanghui.com.

Use of Non-GAAP Financial Measures

The Company has included non-GAAP financial measures in this press release. Non-GAAP financial measures are defined as GAAP gross profit excluding non-cash share-based compensation expenses, operating income excluding non-cash share-based compensation expenses, net income excluding non-cash share-based compensation expenses, net margin excluding non-cash share-based compensation expenses, basic earnings per share and per ADS excluding non-cash share-based compensation expenses, and diluted earnings per share and per ADS excluding non-cash share-based compensation expenses. The Company believes that management and investors benefit from referring to the non-GAAP financial measures in assessing the performance of the Company and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. The use of non-GAAP financial measures has limitations and readers should not consider non-GAAP financial measures in isolation from or as alternatives to consolidated financial metrics prepared in accordance with U.S. GAAP. Readers are encouraged to refer to the reconciliation of non-GAAP measures to GAAP measures included herein.


Safe-Harbor Statement

This press release contains statements of a forward-looking nature, including, among other things, the Company’s unaudited operating results for 2012, expected new product introductions, the demand for orthopedic products in China, future prospects of the Company and the ability for the Company to realize its business plans for 2012. These forward-looking statements are not historical facts but instead represent only the Company’s belief regarding expected results and events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. The actual results and other circumstances of the Company may differ, possibly materially, from the anticipated results and events indicated in these forward-looking statements. Announced results for the second quarter of 2012 are preliminary, unaudited and subject to audit adjustment. Adjustments to the financial statements may be identified when audit work is performed for the year-end audit, which could result in significant differences from this preliminary unaudited financial information. These statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals, and projections, which are subject to numerous assumptions, risks, and uncertainties. These forward-looking statements may include, but are not limited to, statements containing words such as “may,” “could,” “would,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “expects,” “intends” and “future” or similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to change at any time. These forward-looking statements are based upon management’s current expectations and are subject to a number of risks, uncertainties and contingencies, many of which are beyond the Company’s control that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company’s actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including the Company’s beliefs regarding its strengths and strategies; the Company’s ability to expand its international business; the Company’s ability to develop and successfully market new products in China and internationally; the Company’s current expansion strategy, including its ability to expand its manufacturing and research and development facilities and capabilities and the Company’s future prospects, business development, results of operations and financial condition. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 20-F for the fiscal year 2011, as filed with the Securities and Exchange Commission on April 30, 2012, and are available on the Securities and Exchange Commission’s website at www.sec.gov. For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations, and prospects, please see “Risk Factors” that begins on page 6 of the Company’s annual report for fiscal year 2011 and in documents subsequently filed by the Company from time to time with the Securities and Exchange Commission, which can be found on the Company’s website at www.kanghui.com or at www.sec.gov.


Investor Relations Contact Information

Asia Bridge Capital Limited

Wendy Sun

Tel:   86-10-8556-9033 (China)
  1-888-321-2558 (U.S.)

Email: wendy.sun@asiabridgegroup.com


China Kanghui Holdings

Summary – Second Quarter of 2012

(RMB in thousands, except for per share data and per ADS data)

 

     Three Months Ended
June 30,
     Six Months Ended
June 30,
 
     2011      2012      2011      2012  
     Unaudited      Unaudited      Unaudited      Unaudited  

Net revenue

     81,758         101,101         149,733         183,814   

Gross profit

     58,049         71,882         106,765         130,454   

Non-GAAP gross profit

     58,098         72,034         106,864         130,639   

Operating income

     30,374         38,721         60,178         70,207   

Non-GAAP operating income

     31,912         43,087         63,133         77,534   

Net income attributable to China Kanghui Holdings

     27,879         34,766         49,848         64,475   

Non-GAAP net income

     29,417         39,132         52,803         71,802   

Earnings per share – basic

     0.20         0.25         0.36         0.46   

Earnings per share – diluted

     0.18         0.22         0.33         0.41   

Earnings per ADS – basic

     1.21         1.48         2.17         2.75   

Earnings per ADS – diluted

     1.09         1.33         1.96         2.49   

Non-GAAP earnings per share – basic

     0.20         0.28         0.38         0.51   

Non-GAAP earnings per share – diluted

     0.18         0.25         0.35         0.46   

Non-GAAP earnings per ADS – basic

     1.23         1.67         2.30         3.06   

Non-GAAP earnings per ADS – diluted

     1.11         1.50         2.08         2.77   

– Revenue By Product Category

           

Trauma

     47,452         59,450         89,482         111,022   

Spine

     26,260         32,686         45,454         58,579   

OEM

     8,046         8,863         14,797         14,111   

Joint Reconstruction

     —           102         —           102   

– Revenue by Business Sector

           

Domestic

     57,633         77,561         107,742         141,877   

International

     16,079         14,678         27,194         27,827   

OEM

     8,046         8,862         14,797         14,110   


China Kanghui Holdings

Consolidated Balance Sheets

(Expressed in thousands)

 

     As of
December 31,
2011
    As of
June 30,
2012
 
    

RMB

Audited

   

RMB

Unaudited

   

US$

Unaudited

 

Assets

      

Current assets:

      

Cash and cash equivalents

     380,092        432,055        68,008   

Bills receivable

     5,873        4,130        650   

Short-term investments

     76,998        10,300        1,621   

Accounts receivable, net

     87,578        136,619        21,505   

Inventories, net

     110,907        134,280        21,136   

Prepayments and other current assets

     13,428        13,521        2,131   

Deferred tax assets

     9,090        12,124        1,908   

Amount due from related parties

     5,672        4,189        659   
  

 

 

   

 

 

   

 

 

 

Total current assets

     689,638        747,218        117,618   

Non-current assets:

      

Property, plant and equipment, net

     259,825        316,325        49,791   

Intangible assets, net

     62,026        59,857        9,422   

Prepaid land lease payments

     22,812        22,569        3,552   

Goodwill

     155,341        155,341        24,452   

Long-term investments

     25,204        25,412        4,000   

Deposits for non-current assets

     4,731        5,598        881   

Deferred tax assets

     2,444        2,335        368   

Other assets, non-current

     257        34        5   
  

 

 

   

 

 

   

 

 

 

Total non-current assets

     532,640        587,471        92,471   
  

 

 

   

 

 

   

 

 

 

Total assets

     1,222,278        1,334,689        210,089   
  

 

 

   

 

 

   

 

 

 

Liabilities and equity

      

Current liabilities:

      

Accounts payable

     19,278        23,812        3,748   

Accrued expenses and other liabilities

     65,388        98,626        15,524   

Income tax payable

     5,800        8,594        1,353   

Uncertain tax positions

     4,197        4,727        744   

Amount due to related parties

     1,137        1,312        207   
  

 

 

   

 

 

   

 

 

 

Total current liabilities

     95,800        137,071        21,576   

Non-current liabilities:

      

Deferred government grants

     6,409        3,827        602   

Deferred tax liabilities

     14,857        14,474        2,278   
  

 

 

   

 

 

   

 

 

 

Total non-current liabilities

     21,266        18,301        2,880   
  

 

 

   

 

 

   

 

 

 

Total liabilities

     117,066        155,372        24,456   
  

 

 

   

 

 

   

 

 

 

Commitments and contingencies

      

Equity:

      

Ordinary shares (par value of US$0.001 per share; 1,000,000,000 shares authorized as of December 31, 2011 and June 30, 2012 (unaudited); 140,401,842 shares issued and outstanding as of December 31, 2011 and 141,204,612 shares issued and outstanding as of June 30, 2012 (unaudited))

     1,022        1,027        162   

Additional paid-in capital

     912,972        922,625        145,227   

Accumulated other comprehensive loss

     (19,604     (18,954     (2,983

Statutory reserves

     45,417        45,417        7,149   

Retained earnings

     156,387        220,862        34,765   
  

 

 

   

 

 

   

 

 

 

Total China Kanghui Holdings shareholders’ equity

     1,096,194        1,170,977        184,320   

Non-controlling interests

     9,018        8,340        1,313   
  

 

 

   

 

 

   

 

 

 

Total equity

     1,105,212        1,179,317        185,633   
  

 

 

   

 

 

   

 

 

 

Total liabilities and equity

     1,222,278        1,334,689        210,089   
  

 

 

   

 

 

   

 

 

 


China Kanghui Holdings

Consolidated Statements of Comprehensive Income

Expressed in thousands, except for number of shares and per share data

 

     Three Months Ended June 30,     Six Months Ended June 30,  
     2011     2012     2011     2012  
     RMB     RMB     US$     RMB     RMB     US$  
     Unaudited     Unaudited     Unaudited     Unaudited     Unaudited     Unaudited  

Net revenue

     81,758        101,101        15,914        149,733        183,814        28,933   

Cost of revenue

     (23,709     (29,219     (4,599     (42,968     (53,360     (8,399
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     58,049        71,882        11,315        106,765        130,454        20,534   

Operating expenses

            

Selling expenses

     (11,750     (11,648     (1,833     (18,738     (21,408     (3,370

General and administrative expenses

     (14,126     (18,131     (2,854     (24,548     (32,338     (5,090

Research and development expenses

     (1,799     (3,382     (532     (3,301     (6,501     (1,023
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     30,374        38,721        6,096        60,178        70,207        11,051   

Interest income

     2,529        3,274        515        4,248        7,141        1,124   

Government grants

     484        132        21        3,190        283        45   

Other income

     848        477        75        993        962        151   

Other expenses

     (511     (1,471     (232     (908     (1,828     (288

Foreign exchange (loss) gain

     (2,333     25        4        (5,341     (146     (23
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

     31,391        41,158        6,479        62,360        76,619        12,060   

Income taxes

     (3,779     (6,498     (1,023     (12,761     (12,822     (2,018
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     27,612        34,660        5,456        49,599        63,797        10,042   

Net loss attributable to non-controlling interests

     267        106        17        249        678        107   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to China Kanghui Holdings

     27,879        34,766        5,473        49,848        64,475        10,149   

Earnings per share

            

Basic

     0.20        0.25        0.04        0.36        0.46        0.07   

Diluted

     0.18        0.22        0.04        0.33        0.41        0.07   

Shares used in earnings per share computation

            

Basic

     138,702,487        140,757,363        140,757,363        137,770,862        140,598,892        140,598,892   

Diluted

     153,748,894        156,262,908        156,262,908        152,290,642        155,615,320        155,615,320   

Other comprehensive (loss) income, net of tax4

            

Foreign currency translation adjustments

     (271     692        109        (474     650        102   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total other comprehensive (loss) income, net of tax

     (271     692        109        (474     650        102   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income attributable to China Kanghui Holdings

     27,608        35,458        5,582        49,374        65,125        10,251   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Share-based compensation charges incurred during the period related to:

            

Cost of revenue

     49        152        24        99        185        29   

Selling expenses

     109        468        74        221        604        95   

General and administrative expenses

     1,330        3,604        567        2,537        6,366        1,002   

Research and development expenses

     50        142        22        98        172        27   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

     1,538        4,366        687        2,955        7,327        1,153   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 


China Kanghui Holdings

Reconciliations of Non-GAAP Results to GAAP Results of Operations

(RMB in thousands, except for share, ADS, per share data and per ADS data)

 

     Three Months Ended
June 30,
    Six Months Ended
June 30,
 
     2011     2012     2011     2012  
     Unaudited     Unaudited     Unaudited     Unaudited  

Net revenue

     81,758        101,101        149,733        183,814   

Non-GAAP net income

     29,417        39,132        52,803        71,802   

Non-GAAP net margin

     36.0     38.7     35.3     39.1

Share-based compensation

     (1,538     (4,366     (2,955     (7,327
  

 

 

   

 

 

   

 

 

   

 

 

 

GAAP net income

     27,879        34,766        49,848        64,475   

GAAP net margin

     34.1     34.4     33.3     35.1

Non GAAP earnings per share – basic

     0.20        0.28        0.38        0.51   

Non GAAP earnings per share – diluted

     0.18        0.25        0.35        0.46   

Non GAAP earnings per ADS – basic

     1.23        1.67        2.30        3.06   

Non GAAP earnings per ADS – diluted

     1.11        1.50        2.08        2.77   

GAAP earnings per share – basic

     0.20        0.25        0.36        0.46   

GAAP earnings per share – diluted

     0.18        0.22        0.33        0.41   

GAAP earnings per ADS – basic

     1.21        1.48        2.17        2.75   

GAAP earnings per ADS – diluted

     1.09        1.33        1.96        2.49   

Shares used in computation of:

        

Basic earnings per share

     138,702,487        140,757,363        137,770,862        140,598,892   

Diluted earnings per share

     153,748,894        156,262,908        152,290,642        155,615,320   

Basic earnings per ADS

     23,117,081        23,459,561        22,961,810        23,433,149   

Diluted earnings per ADS

     25,624,816        26,043,818        25,381,774        25,935,887   

Non-GAAP operating income

     31,912        43,087        63,133        77,534   

Non-GAAP operating margin

     39.0     42.6     42.2     42.2

Share-based compensation

     (1,538     (4,366     (2,955     (7,327
  

 

 

   

 

 

   

 

 

   

 

 

 

GAAP operating income

     30,374        38,721        60,178        70,207   

GAAP operating margin

     37.2     38.3     40.2     38.2

Non-GAAP gross profit

     58,098        72,034        106,864        130,639   

Non-GAAP gross margin

     71.1     71.2     71.4     71.1

Share-based compensation

     (49     (152     (99     (185
  

 

 

   

 

 

   

 

 

   

 

 

 

GAAP gross profit

     58,049        71,882        106,765        130,454   

GAAP gross margin

     71.0     71.1     71.3     71.0